208 related articles for article (PubMed ID: 6252831)
21. Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.
Magnussen CR; Sammartino MT; Ernest KD
Antimicrob Agents Chemother; 1982 Jul; 22(1):154-6. PubMed ID: 6289736
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
Verbist L; Verhaegen J
Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
Braveny I; Machka K; Elsser R
Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
[TBL] [Abstract][Full Text] [Related]
24. Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
Mintz L; Drew WL
Antimicrob Agents Chemother; 1981 Feb; 19(2):332-4. PubMed ID: 6289731
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of antimicrobial activity and stability to beta-lactamases of cefoperazone, cefotaxime, lamoxactam and ceftriaxon].
Baumgärtner M; Grehn M; Wundt W
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):208-21. PubMed ID: 6289564
[TBL] [Abstract][Full Text] [Related]
26. Differences among moxalactam, cefoperazone, and cefotaxime in activity against multiple-antibiotic-resistant gram-negative bacteria.
Preston DA
Rev Infect Dis; 1982; 4 Suppl():S516-21. PubMed ID: 6296965
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzae.
Jorgensen JH; Crawford SA; Alexander GA
Antimicrob Agents Chemother; 1980 Mar; 17(3):516-7. PubMed ID: 6252832
[TBL] [Abstract][Full Text] [Related]
28. Susceptibility of Pseudomonas aeruginosa to cefoperazone, cefotaxime and moxalactam, with special reference to isolates resistant to aminoglycosides, carbenicillin and ticarcillin.
Woolfrey BF; Fox JM; Quall CO
J Antimicrob Chemother; 1981 Sep; 8(3):205-11. PubMed ID: 6270052
[No Abstract] [Full Text] [Related]
29. Combination of mezlocillin and azlocillin with cephalosporin antibiotics: cefoxitin, cefoperazone, cefotaxime and moxalactam.
Neu HC; Labthavikul P
J Antimicrob Chemother; 1982 Jan; 9 Suppl A():101-6. PubMed ID: 6281229
[No Abstract] [Full Text] [Related]
30. In vitro comparison of three new cephalosporins: LY-127935, cefotaxime and cefoperazone.
Trager GM; White GW; Zimelis VM; Bryk DA; Panwalker AP
Chemotherapy; 1981; 27(1):34-8. PubMed ID: 6260435
[TBL] [Abstract][Full Text] [Related]
31. In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.
Shelton S; Nelson JD; McCracken GH
Antimicrob Agents Chemother; 1980 Sep; 18(3):476-9. PubMed ID: 6252837
[TBL] [Abstract][Full Text] [Related]
32. Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.
Dabernat HJ; Delmas C
Rev Infect Dis; 1982; 4 Suppl():S401-5. PubMed ID: 6294790
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.
O'Donnell ED; Freimer EH; Gilardi GL; Raeder R
Antimicrob Agents Chemother; 1982 Apr; 21(4):673-5. PubMed ID: 6211143
[TBL] [Abstract][Full Text] [Related]
34. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
[TBL] [Abstract][Full Text] [Related]
35. In vitro evaluation of cefoperazone.
Hinkle AM; LeBlanc BM; Bodey GP
Antimicrob Agents Chemother; 1980 Mar; 17(3):423-7. PubMed ID: 6448578
[TBL] [Abstract][Full Text] [Related]
36. Correlation of moxalactam (LY127935) susceptibility tests by disk diffusion and agar plate dilution methods.
Hall WH; Opfer BJ
Antimicrob Agents Chemother; 1981 Jan; 19(1):130-3. PubMed ID: 6454380
[TBL] [Abstract][Full Text] [Related]
37. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
Eickhoff TC; Ehret J
Antimicrob Agents Chemother; 1981 Mar; 19(3):435-42. PubMed ID: 6264845
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
Livermore DM; Williams RJ; Williams JD
J Antimicrob Chemother; 1981 Oct; 8(4):323-31. PubMed ID: 6271726
[No Abstract] [Full Text] [Related]
39. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
Fitzpatrick BJ; Standiford HC
Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of ceftazidime and ceftriaxone.
Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
